Literature DB >> 12789292

Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil.

Gang Li1, Kapaettu Satyamoorthy, Friedegund Meier, Carola Berking, Thomas Bogenrieder, Meenhard Herlyn.   

Abstract

Melanoma development and progression not only involve genetic and epigenetic changes that take place within the melanocytic cells, but also involve processes that are determined collectively by contextual factors including intercellular adhesions and communications. In this review, we focus on melanoma-stromal fibroblast crosstalk by direct cell-cell contact and by growth factors/cytokines/chemokines interacting with their respective receptors. The interactions between melanoma cells and stromal fibroblasts create a context that promotes tumor growth, migration/invasion, and angiogenesis. An understanding of this process and developing new experimental and screening models are of great importance for the development of effective therapeutical strategies to treat melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789292     DOI: 10.1038/sj.onc.1206455

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 2.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

3.  Fibroblasts contribute to melanoma tumor growth and drug resistance.

Authors:  Edward H Flach; Vito W Rebecca; Meenhard Herlyn; Keiran S M Smalley; Alexander R A Anderson
Journal:  Mol Pharm       Date:  2011-11-08       Impact factor: 4.939

4.  Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.

Authors:  Kerrington R Molhoek; Amber L Shada; Mark Smolkin; Sudhir Chowbina; Jason Papin; David L Brautigan; Craig L Slingluff
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

5.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

Review 6.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

8.  Targeted deactivation of cancer-associated fibroblasts by β-catenin ablation suppresses melanoma growth.

Authors:  Linli Zhou; Kun Yang; R Randall Wickett; Ana Luisa Kadekaro; Yuhang Zhang
Journal:  Tumour Biol       Date:  2016-08-29

Review 9.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity.

Authors:  Mirna Balsamo; Francesca Scordamaglia; Gabriella Pietra; Claudia Manzini; Claudia Cantoni; Monica Boitano; Paola Queirolo; William Vermi; Fabio Facchetti; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari; Massimo Vitale
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.